Familial cortical myoclonic tremor with epilepsy (FCMTE) is an autosomal dominant epilepsy syndrome with considerable clinical and genetic heterogeneity. The most important clinical manifestations include adult onset, cortical myoclonic tremor, with or without epileptic seizures. Of the four loci reported, which included 8q24 (FCMTE1), 2p11.1-q12.2 (FCMTE2), 5p15.31-p15.1 (FCMTE3), and 3q26.32-3q28 (FCMTE4), only one probably causative mutation was found co-segregated in two FCMTE2 pedigrees in the a 2 -adrenergic receptor subtype B (ADRA2B) gene. In this review we discuss studies that focused on the molecular genetics of FCMTE, its neuropathology, clinical, neurophysiological and neuroimaging features, which may offer useful clues for the search for causative FCMTE genes. Next-generation sequencing has identified many causative genes in monogenic diseases. However, most next-generation sequencing applications focus on detecting single nucleotide variants or small insertions/deletions, which do not completely resolve the challenge of identifying causative genes in FCMTE. Recent progress in exploring FCMTE has revealed that special mutations such as copy number variants, exon rearrangements and large trinucleotide repeat expansion (or polynucleotide repeat expansion) should be considered. Clues from neuropathological, clinical, neurophysiological and neuroimaging studies indicate that the candidate causative genes should be expressed in the cerebellum, especially in Purkinje cells, and be associated with calcium signaling and GABA receptors. We propose that the developing novel algorithms of next-generation sequencing data, which could detect structure variants and candidate causative gene selection when combined with special mutations detection analysis represent possible future direction of a rational search for causative genes in FCMTE.
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proposed that BAFME, ADCME, FAME, FCMT, FCTE, FEME, FMEA, and HTE should be regarded as integral components of one disease spectrum named as FCMTE and a diagnostic criterion for FCMTE was subsequently proposed [2] . With the identified clinical and electrophysiological features, FCMTE is a well-defined epilepsy syndrome that still awaits nosological placement in the International League Against Epilepsy (ILAE) classification [4] . Four loci were identified including 8q24 (FCMTE1), 2p11.1-q12.2 (FCMTE2), 5p15.31-p15.1 (FCMTE3) and 3q26.32-3q28 (FCMTE4), and several possibly/probably causative genes were also reported (see Tables 1 and 2 ). However, a significant gap remains between the real causative genes and FCMTE [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Herein, we have reviewed previous molecular genetic studies of FCMTE and associated advances in neuropathological, clinical, neurophysiological and neuroimaging studies. We aim to provide possible explanations for the difficulties of previous studies to identify causative genes of FCMTE, and to offer future directions for the search for causative genes of FCMTE.
Recent advances in the identification of causative gene region
FCMTE pedigrees were previously reported in Japan, Italy, France, Thailand, Spain and China with considerable genetic heterogeneity. Great effort has been made recently, and four loci including 8q24 (FCMTE1), 2p11.1-q12.2 (FCMTE2), 5p15.31-p15.1 (FCMTE3) and 3q26.32-3q28 (FCMTE4) have been identified (see Table 1 ) [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .
FCMTE1 (OMIM 601068) was the first locus that identified in a large pedigree (i.e., FCMTE1 No.1), and four small pedigrees (i.e., FCMTE1 No.2-5) from Japan. Plaster et al. localized four small pedigrees (i.e., FCMTE1 No.2-5) to a relatively small region (i.e., a 4.6 cM interval from D8S514 to D8S1804) in 1999 [6] . However, we noticed that in the five microsatellite markers (i.e., D8S514, D8S1826, 572-18, D8S384 and D8S1804) they chose for haplotype analysis, the physical positions of D8S384, D8S514 and D8S1826 should be chr8: 118456019-118456384, chr8: 123742103-123742461 and chr8: 123856163-123856442. The position of microsatellite markers above were mixed in an incorrect array due to limited information at that time. Herein, we have analyzed their haplotype and identified that the downstream boundary of causative gene region was D8S514. The large pedigree of FCMTE1 (i.e., FCMTE1 No.1) was firstly localized to an 8 cM interval (i.e., between D8S1784 and D8S1694) by Mikami et [17] . Dozens of candidate genes in FCMTE2 locus have been screened and only one probably causative mutation in the ADRA2B gene was co-segregated in two pedigrees (i.e., FCMTE2 No.1 and No.11), which shared a common ancestor [18] . No SNVs, small insertions/deletions (indels), or large indels in the ADRA2B gene was detected in the other two FCMTE2 pedigrees (i.e., FCMTE2 No.4 and No.6) [18] . Until now, no other mutation in ADRA2B has been reported in other FCMTE pedigrees. These indicate that additional evidence is needed to confirm whether or not ADRA2B is the authentic causative gene in FCMTE2 locus, while the search for a second causative gene in this locus is still formally possible.
FCMTE3 (OMIM 613608) was reported in a French pedigree (i.e., FCMTE3 No.1) and a Chinese pedigree (i.e., FCMTE3 No.2) [19, 20, 22] . Sanger sequencing of two candidate genes (SEMA5A and CTNND2) in FCMTE3 No.1 pedigree did not detect any causative mutation [18] . FCMTE4 (OMIM 615127) was only reported in a Thai pedigree (i.e., FCMTE4 No.1) without causative gene identified [21] .
Although next-generation sequencing (NGS) like WES and whole-genome sequencing (WGS) can detect the causative mutation without causative gene regional information, localization of causative gene remains very important in causative gene identification, especially when NGS fails to detect the causative mutation. With increasing numbers of FCMTE pedigrees being mapped, narrowing of the reported causative gene regions should be helpful for identification of the causative genes.
Recent advances in possibly/probably causative genes of FCMTE and similar phenotypes
Recently, some possibly/probably causative genes of FCMTE and similar phenotypes have been reported (see Table 2 ) [18, [23] [24] [25] [26] .
In 2012, Kato et al. reported a rare missense mutation c.5720G>A (p.Arg1907His) of the UBR5 (i.e., ubiquitin protein ligase E3 component n-recognin 5, 8q22.3) gene in a Japanese FCMTE pedigree without localization analysis [23] . Mutations in the genes encoding E3 ubiquitin-protein ligases were associated with hereditary neurological diseases including Angelman syndrome and autosomal recessive juvenile Parkinsonism, which provided evidence that a rare mutation in UBR5 could be associated with FCMTE [23] .
In 2012, Russell et al. reported a Canadian pedigree with familial cortical myoclonic (FCM), which is characterized by autosomal dominant, adult onset and cortical myoclonus without associated seizures. Additionally, EMG detected g-SEP in some affected members. Combining linkage analysis and WES, a rare missense mutation c.61G>C (p.Glu21Gln) in the NOL3 (i.e., nucleolar protein 3, 16q22.1) gene that encodes nucleolar protein 3 was co-segregated in the pedigree. The c.61G>C mutation alters post-translational modification of nucleolar protein 3 in cells. However, NOL3 knockout mice did not exhibit any overt motor phenotype, including myoclonus and SEP was statistically equivalent when comparing NOL3 knockouts and WT mice [24] .
In 2013, Stogmann et al. reported a consanguineous Egyptian pedigree with autosomal recessive cortical myoclonic tremor and epilepsy. All five affected members in the pedigree experienced GTCS and presented with CMT in adolescence. Combining linkage analysis and WES, they identified a rare frameshift mutation c.503delG (p.Trp168CysfsX163) of the CNTN2 (i.e., contactin 2, 1q32.1) gene, which co-segregated in the pedigree [25] . CNTN2-deficient mice showed spontaneous epileptic seizures and increased seizure susceptibility to convulsive stimuli [27] . This observation highly supported the role of the CNTN2 gene as the underlying causative gene in this pedigree and phenotype.
In 2013, Marti-Masso et al. detected a rare nonsense mutation c.77G>A (p.Trp26X) by WES in the ACMSD (i.e., a-amino-b-
carboxymuconate-e-semialdehyde decarboxylase, 2q21.3) gene, which co-segregated in a Spanish FCMTE pedigree [26] . ACMSD is a component of the kynurenine pathway, which has already been identified in the genesis of epileptic seizures [28, 29] . [8] .
Several possibly/probably FCMTE genes were reported when using WES. However, none of the genes had sufficient evidence to guarantee their association with FCMTE. Those reports all could not detect different mutations of the possibly/probably causative genes in multiple independent pedigrees with the same or similar phenotypes and no other research group has yet confirmed these results [30] .
Recent advances in related studies offered clues for candidate gene selection
Although six possibly/probably FCMTE and similar phenotypeassociated genes have been reported, ADRA2B was the only probably causative gene in the previously reported FCMTE locus (FCMTE2) [18] . Causative genes in FCMTE1, FCMTE3 and FCMTE4, and even some FCMTE2 pedigrees (i.e., FCMTE2 No.4 and No.6) remain unknown. This indicates that NGS is insufficient to resolve the challenge of identifying causative genes in FCMTE. Recently, some neuropathological, clinical, neurophysiological and neuroimaging studies of FCMTE were reported, which may offer useful information for candidate gene selection and clues for further study (see Fig. 1 ). pedigree, all of which showed marked loss and morphological changes (i.e., somal sprouting and loss of the dendritic tree) of Purkinje cells in the cerebellar cortex with no or limited changes in the sensorimotor cortex [31] [32] [33] . Another post-mortem neuropathological study of an FCMTE patient from a South African pedigree also showed Purkinje cells loss, dentate atrophy and neuronal cell loss, with gliosis in the olives and pallidum [34] . These neuropathological studies indicated that the cerebellum was involved in the pathophysiology of FCMTE, which showed remarkable similarities to changes that were described in SCA6, a pure cerebellar syndrome caused by a CACNA1A mutation [35] . In addition, Purkinje cells dysfunction and loss were the major pathophysiological changes seen in some other spinocerebellar ataxias (SCAs) (i.e., SCA1, 2, 3, 5, 14, 15 and 16), and deranged calcium signaling was linked to the pathogenesis of these SCAs [36] . Their mutant proteins (Ataxin1, Ataxin2, Ataxin3, b-III spectrin, CACNA1A, PKCg and ITPR1) affected calcium signaling of Purkinje cells in the cerebellum, which could cause Purkinje cells dysfunction and loss [36] . These studies suggested that causative genes of FCMTE might share similar functions with these SCAs genes described above in the role of calcium signaling in Purkinje cells at the cerebellum.
Updated studies on neuropathology
In the cortical myoclonus (CM), a group of diseases that also includes FCMTE and different types of progressive myoclonic epilepsy (PME), the cerebellum has been widely suggested as playing an important role in disease pathogenesis [37] [38] [39] . Ganos et al. concluded that the cerebellum played a key role in motor control and adaptation by its inhibitory function on the cortex through the cerebello-thalamo-cortical loop where inhibitory neurotransmission-GABA receptors play key roles [38, 39] . This indicated that genes associated with the GABA receptors might be causative genes of FCMTE.
The above described studies on neuropathology suggest that the causative genes of FCMTE might be linked to the SCAs (i.e., SCA1, 2, 3, 5, 14, 15 and 16) genes, calcium signaling in Purkinje cells at the cerebellum and the GABA receptors. 
Updated studies on clinical and neurophysiology
In 2012, clinical anticipation was reported in four Japanese FCMTE pedigrees [40] . Clinical anticipation was usually observed in diseases caused by trinucleotide repeats (or polynucleotide repeats), for example in Dentatorubral-pallidoluysian atrophy (DRPLA) and some types of SCAs. In 2013, the same group observed clinical anticipation in all 12 FCMTE parent/child pairs (i.e., 8 mother/child pairs and 4 father/child pairs) with regard to either CMT or GTCS. A higher degree of clinical anticipation was associated with maternal transmission [41] . These observations suggested that trinucleotide repeat expansion (or polynucleotide repeat expansion) should be considered in FCMTE.
In 2007, van Rootselaar et al. found that FCMTE patients presented with significantly reduced short-interval intracortical inhibition (SICI), which indicated functional changes of the motor cortex [32] . SICI was thought to occur through a GABAA-ergic inhibitory postsynaptic potential [40] . In addition, the symptoms in FCMTE diminished with clonazepam and valproic acid, which were both GABA-ergic drugs [2] . These results further support the notion that genes that are associated with GABA receptors might be causative genes of FCMTE.
More interestingly, reduced SICI was also detected in patients from four different German pedigrees with different mutations in SCA14, which is a complicated form of SCAs that presents as dystonia and myoclonus in addition to a slowly progressive cerebellar ataxia [42] . Combining the neuropathology results of the loss of Purkinje cells and abnormal Purkinje cells morphology, and the reduced SICI, the cortical hyperexcitability might be due to deficient cerebellar Purkinje cells inhibition via the cerebello-thalamo-cortical loop in both FCMTE and SCA14. Eye movement recordings that showed downbeat positioning nystagmus (DBN) and square wave jerks were also detected in these FCMTE patients, which indicated cerebellar dysfunction [32] . DBN was also detected in SCA6 patients, which shared remarkable changes in neuropathological studies with FCMTE [43] .
The above discussed studies on the clinical and neurophysiology suggest that dysfunction of the cerebellum was shared between FCMTE and SCAs. In addition, the clinical anticipation in FCMTE further supported common features between them, which indicated that trinucleotide repeat expansion (or polynucleotide repeat expansion) should be considered in FCMTE.
Updated studies on neuroimaging
In 2009, Striano et al. investigated the neurochemical patterns in FCMTE2 patients with proton magnetic resonance spectroscopy ( 1 H-MRS). Elevated choline/creatine ratio (which indicated mild neuronal loss with consequent gliosis) in the cerebellar cortex was found. However, no difference in metabolite ratios in the frontal and occipital cortex between patients and controls was found [44] . In 2015, Long et al. also detected decreased N-acetylaspartate/choline ratios, which reflected neuronal loss and secondary astrocytosis in the cerebellar cortex [45] . These studies suggested that the cerebellum was a prominent site of dysfunction in FCMTE. Metabolic change in the cerebellar hemispheres was also reported in patients with Lafora disease (another type of CM), which indicated similar physiopathologic mechanisms between FCMTE and Lafora disease.
In 2012, Buijink et al. compared cerebellar fiber density between healthy controls, patients with FCMTE and essential tremor (ET) by MR diffusion tensor imaging. They found a significantly decreased mean fractional anisotropy (FA) in FCMTE patients that indicated microstructural damage of the cerebellar white matter in FCMTE in vivo [46] . Cerebellar white matter damage can potentially alter the cerebello-thalamo-cortical loop, and thereby increase tonic facilitation of the motor cortex [46] . These neuroimaging studies further supported that cerebellum played an important role in FCMTE.
Future direction for causative gene identification in FCMTE
Before NGS became the main tool for identification of causative genes in monogenic diseases, linkage analysis combined with candidate gene sequencing was the classical strategy for monogenic diseases causative gene identification. Herein, we reviewed previously reported studies on neuropathology, clinical features, neurophysiology and neuroimaging in FCMTE. We propose four conditions that candidate causative genes in the loci of FCMTE may be associated with: (1) Genes encoding proteins that are expressed in the cerebellum, especially in the cerebellar cortex and Purkinje cells. (2) Genes encoding proteins that are associated with calcium signaling. (3) Genes encoding proteins that are associated with GABA receptors. (4) Genes that interact with genes of specific SCAs (i.e., SCA1, 2, 3, 5, 6, 14, 15/16) and some neurophysiologically proven or clinically suspected CM (PME including Unverricht-Lundborg disease, MERRF, neuronal ceroid lipofuscinosis, DRPLA, Gaucher disease, Lafora disease and sialidosis). This information is not only helpful for the selection of candidate causative genes in FCMTE, but it is also useful in the identification of causative genes and further functional studies.
Although only reported by one group, clinical anticipation in Japanese FCMTE pedigrees indicated trinucleotide repeat expansion (or polynucleotide repeat expansion) might be the causative mutation type of FCMTE [40] . Similar neuropathological, clinical, neurophysiological and neuroimaging features shared between FCMTE and SCAs also hint that there may be similar mechanisms shared between them. The trinucleotide repeat expansion (or polynucleotide repeat expansion) could be located in the coding or non-coding regions. If the size of the expansion was large (i.e., approximately more than 80 bp for trinucleotide repeat expansion or larger as is seen for large expansions of CGG in Fragile X syndrome), NGS would not be suitable to detect it [47] . Other special methods like Southern blot analysis could be used to detect these mutations, if indeed there was a suspected candidate gene.
Most NGS applications focus on the detection of SNVs or small insertions/deletions (indels), which may miss some mutation types like exon rearrangements, trinucleotide repeat expansion (or polynucleotide repeat expansion) and CNVs. Recently, novel algorithms of NGS were applied in the detection of these mutation types [48] [49] [50] [51] . These novel algorithms might offer further useful information for the identification of causative genes in FCMTE. However, caution should be observed with regard these novel algorithms since they still suffer from some limitations that might miss some of these mutation types [47, 52] .
Conclusions
Combining the reports we have reviewed, we suggest that the causative genes of FCMTE might be harboring a special type of mutation which could not be detected by classical NGS bioinformatics analysis. The encoding protein might be expressed in the cerebellum, especially in the cerebellar cortex and Purkinje cells, and might be associated with calcium signaling and GABA receptors. The causative genes might also interact with genes of some SCAs (i.e., SCA1, 2, 3, 5, 6, 14, 15/16) and some neurophysiologically proven or clinically suspected CM.
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